Tech Mahindra Unveils AI-Powered PV Solution in Collaboration with NVIDIA

Built on Tech Mahindra's TENO framework and integrated with NVIDIA AI Enterprise software, the solution handles critical PV tasks such as case intake, data transformation, quality control, and compliance management.

Tech Mahindra has introduced an advanced pharmacovigilance (PV) solution powered by NVIDIA AI to enhance drug safety management.

The AI-driven solution aims to improve the accuracy, speed, and efficiency of pharmacovigilance processes by automating key workflows and addressing industry challenges such as data overload and manual processing delays.

Tech Mahindra's new solution leverages agentic artificial intelligence (AI) and automation to streamline pharmacovigilance operations.

Built on Tech Mahindra's TENO framework and integrated with NVIDIA AI Enterprise software, the solution handles critical PV tasks such as case intake, data transformation, quality control, and compliance management.

The solution incorporates NVIDIA NeMo, NVIDIA NIM microservices, and NVIDIA AI Blueprints to ensure a seamless and intelligent PV workflow.

The AI-powered large language model (LLM) agents autonomously manage case classification, prioritization, and verification of pharmacovigilance reports, reducing human error and improving response times.

Nikhil Malhotra, Chief Innovation Officer and Global Head of AI and Emerging Technologies at Tech Mahindra, stated, "As the pharmaceutical industry navigates volumes of data during trials and post-launch, our collaboration with NVIDIA leverages generative AI and multi-agent systems to streamline pharmacovigilance processes."

Enhancing Accuracy & Reducing Costs

Pharmacovigilance is a critical aspect of drug safety, handling over 1,000 adverse drug reaction (ADR) cases daily for major drugs.

The AI-driven PV solution instantly flags and processes ADR reports, minimizing human intervention and the risk of delays.

According to Tech Mahindra, the solution can reduce turnaround times by up to 40%, improve data accuracy by 30%, and cut operational costs by 25%.

This ensures faster case processing, enhanced regulatory compliance, and proactive risk management, transforming pharmacovigilance from a reactive to a predictive model.

John Fanelli, Vice President of Enterprise Software at NVIDIA, highlighted the significance of AI in drug safety monitoring, "AI is ideal for monitoring medicines throughout their lifecycle to support safety. Integrating AI into the Tech Mahindra TENO framework with NVIDIA AI Enterprise software enhances pharmacovigilance by augmenting human capabilities to help identify potential safety issues more effectively."

Expanding the TENO Framework with AI Capabilities

Tech Mahindra has expanded its TENO framework to incorporate NVIDIA AI Enterprise, equipping it with customized AI agents to tackle a wide range of industry challenges.

The framework uses NVIDIA NeMo to accelerate the generative AI pipeline for data collection and curation.

The framework also integrates Tech Mahindra's VerifAI solution for data validation and governance, ensuring high data accuracy and compliance. Its distributed training and model customization capabilities enable the continuous evolution of AI models, enhancing decision-making precision over time.

Stay tuned for more such updates on Digital Health News.